Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Generic quality of life measures · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse events Pain persisting longer than 2 hours after treatment (during the 3‐week treatment period) · patients with adhesive capsulitis (frozen shoulder)
Combination of manual therapy, exercise, electrotherapy and oral NSAID may leads to higher adverse events Pain persisting longer than 2 hours after treatment… compared with oral NSAID (low certainty).
1 finding from 1 review
Intervention not reported
Achieved recovery according to predetermined criteria (no longer meeting criteria for depression on K‐SADS or meeting a priori criteria for response on a depression checklist, assessed between 4 and 10 weeks of onset of treatment) · children and adolescents with depression
The intervention showed no clear difference in achieved recovery according to predetermined criteria (no longer… (low certainty).
1 finding from 1 review
No clinically important response to treatment ‐ short term · patients with schizophrenia
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes no clinically important response to treatment ‐ short term (3 weeks… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mortality: in‐hospital mortality (within 24 hours) · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: in‐hospital mortality (within 24 hours) compared with longer storage duration (low certainty).
1 finding from 1 review
Mortality: in‐hospital mortality (within 7 days) · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: in‐hospital mortality (within 7 days) compared with longer storage duration (very low certainty).
1 finding from 1 review
Mortality: time‐point not defined · all conditions
It is very uncertain whether transfusion of RBCs of shorter changes mortality: time‐point not defined compared with longer storage duration (very low certainty).
1 finding from 1 review
Mortality: short term (up to 30 days) · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: short term (up to 30 days) compared with longer storage duration (low certainty).
1 finding from 1 review